WIRB-Copernicus Group (WCG) announced it has acquired MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as the CEO of the combined organization. Financial details about the transaction were not disclosed.
WCG will provide clients a more comprehensive and integrated suite of study start-up solutions.
“We are pleased to welcome the dedicated, knowledgeable, and highly skilled teams of MedAvante and ProPhase and delighted to add Dr. Jeff Litwin as the CEO of this important addition to our organization,” Donald A. Deieso, PhD, chairman and chief executive officer of WCG said. “To accelerate the development of life-saving therapies for the patients who need them is our priority. We seek partners who share our vision of increasing efficiencies in the clinical trial process through the intelligent application of innovation, clinical expertise, and technology.” He added, “MedAvante and ProPhase have a proven track record and long-standing history in the CNS space – pioneering ingenious solutions to some of pharma’s most intractable problems with the best and most current thinking in this field.”
“My co-founder, Amy Ellis, and I launched MedAvante to conceive and globalize innovations to improve the lives of patients,” Paul M Gilbert, co-founder & chief executive officer said. “We're thrilled to become part of WCG, which has the resources and capabilities to help us achieve the next level of our vision.”
“We are excited to be joining WCG and combining forces with another market leader to transform how novel treatments are brought to market and improve treatment options and outcomes for all stakeholders,” said principals Sofija Jovic, PhD, MBA, chief executive officer and Mark Opler, PhD, MPH, chief scientific officer and founder at ProPhase.
WCG will provide corporate support to these two organizations as they continue to expand, with access to capital, and complementary clinical and regulatory expertise.